Dans l’affaire Sanofi-Aventis Canada Inc. v. Laboratoire Riva Inc., 2008 FC 291, (March 4, 2008), le tribunal a réitéré les principes de base de l’incitation à la contrefaçon (induced infringement) dans le domaine des médicaments:
 In AB Hassle v. Canada (Minister of National Health and Welfare), 2001 FCT 1264,  F.C.J. No. 1725 (QL) (AB Hassle); affirmed 2002 FCA 421,  F.C.J. No. 1533 (QL), application for leave to appeal to the Supreme Court of Canada dismissed  S.C.C.A. No. 531 (QL), the Federal Court of Canada articulated the test for inducing and procuring infringement at para. 68 as follows:
A patentee wishing to rely on the doctrine of induced infringement must allege and prove each of the following elements:
(a) that the act of infringement was completed by the direct infringer;
(b) the completed act of infringement was influenced by the seller, to the point where without said influence, infringement by the buyer would not otherwise take place; and,
(c) the influence must knowingly be exercised by the seller, such that the seller knows that his influence will result in the completion of the act of infringement.
 In Sanofi-Aventis Canada Inc. v. Novopharm Ltd., 2007 FCA 167,  F.C.J. No. 582 (QL) (Sanofi-Aventis), the Federal Court of Appeal found that an allegation of non-infringement of a claim for the use of a medicine is justified if the generic drug manufacturer is seeking an NOC only for a use that is not within the new use claim and the evidence fails to establish that the generic drug producer will infringe the new use claim by inducing others to prescribe or use the generic product for that new use.
 In Sanofi-Aventis, above at para. 11, Justice Sharlow provided examples of how infringement by inducement may be established:
A generic drug manufacturer may be implicated in the infringement by others of a claim for a new use of a medicine if the generic drug manufacturer induces that infringement. Infringement by inducement may be established, for example, by inferences reasonably drawn from the contents of the product monograph for the generic drug product, or evidence relating to the dosage form of the generic product, or its labelling or marketing.